Arrowstreet Capital
KYMR icon

Arrowstreet Capital’s Kymera Therapeutics KYMR Stock Holding History

Arrowstreet Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-54,574
Closed -$3.21M – 1590
2021
Q3 		$3.21M Buy
+54,574
New +$3.16M ﹤0.01% 1043

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Arrowstreet Capital's KYMR Position: Q4 2021 in Review

Arrowstreet Capital sold out of Kymera Therapeutics (KYMR) in Q4 2021, closing a stake of 54,574 shares — an estimated $3.21M sold.

Arrowstreet Capital first reported a position in KYMR in Q3 2021 and held it in 1 quarter. The position peaked at $3.21M in Q3 2021. 128 funds tracked by Wall St. Rank hold KYMR as of Q4 2021.

  • Arrowstreet Capital reported no remaining Kymera Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 54,574 Kymera Therapeutics shares in Q4 2021, an estimated $3.21M.
  • Arrowstreet Capital first reported a position in Kymera Therapeutics in Q3 2021 and held it in 1 quarter.
  • Arrowstreet Capital's Kymera Therapeutics position peaked at $3.21M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2021.

Based on Arrowstreet Capital's 13F filing for Q4 2021, filed 14 Feb 2022.